Efficacy of budesonide combined with cefoperazone sodium and sulbactam sodium in the treatment of neonatal pneumonia and its influence on serum inflammatory factors
Abstract
To analyze the efficacy of budesonide combined with cefoperazone sodium and sulbactam sodium in neonatal pneumonia, and observe its effect on serum inflammatory indicators. 96 patients with neonatal pneumonia admitted to our hospital from January 2023 to January 2024 were selected as the research objects, and they were divided into a control group and an observation group using random number table method, with 48 cases in each group. The control group was treated with speridone and sulbactam, and the observation group was treated with budesonide on the basis of the control group. The clinical efficacy, lung function indicators [peak volume ratio (VPEF/VE), peak expiratory flow (TPEF/TE)], and serum inflammatory factors [C-reactive protein (CRP), interleukin-6 (IL-6), matrix metalloproteinase 9 (MMP- 9) and leukotriene B4 (LTB4)] levels were compared between the two groups. Compared the clinical efficacy of the two groups, the levels of VPEF/VE, TPEF/TE and PEF in the observation group were higher than those in the control group (P <0.05); after treatment, the levels of VPEF/VE, TPEF/TE and PEF in the study group were higher than those in the control group (P<0.05); after treatment, the levels of CRP, IL- 6, MMP-9 and LTB4 in the observation group were significantly lower than those in the control group (P<0.05). Budesonide combined with cefoperazone sodium and sulbactam sodium in the treatment of neonatal pneumonia can improve clinical efficacy, improve lung function, and reduce serum inflammatory factor levels.
References
[1]Alriyami A, Kiger J R, Hooven T A. Ventilator-Associated Pneumonia in the Neonatal Intensive Care Unit[J]. Neoreviews, 2022,
23(7): e448-e461.
[2]Nair N S, Lewis L E, Dhyani V S, et al. Factors Associated With Neonatal Pneumonia and its Mortality in India: A Systematic Review and Meta-Analysis[J]. Indian Pediatr, 2021, 58(11): 1059-1061.
[3]Domingo-Alemán P, Sampériz-Sinovas L, Martínez-Tourné A, et al. Early-onset neonatal round pneumonia[J]. Pediatr Pulmonol,
2023, 58(1): 358-359.
[4]Bondarev D J, Ryan R M, Mukherjee D, et al .The spectrum of pneumonia among intubated neonates in the neonatal intensive care
unit[J]. J Perinatol, 2024, 44(9): 1235-1243.
[5]Rong Z, Mo L, Pan R, et al. Bovine surfactant in the treatment of pneumonia-induced-neonatal acute respiratory distress syndrome
(NARDS) in neonates beyond 34 weeks of gestation: a multicentre, randomized, assessor-blinded, placebo-controlled trial[J]. Eur J Pediatr,
2021, 180(4): 1107-1115.
[6]Lin M, Zhu S, Weng H, et al. Effect of cefoperazone sulbactam sodium combined with meropenem on the immune function in the
treatment of neonatal pneumonia caused by multidrug-resistant bacteria[J]. Am J Transl Res, 2021, 13(6): 6342-6351.
[7]Amirault J P, Porter J J, Hirsch A W, et al. Diagnosis and Management of Pneumonia in Infants Less Than 90 Days of Age[J]. Hosp
Pediatr, 2023, 13(8): 694-707. doi:10.1542/hpeds. 2022- 007062
[8]Basheer F, Aatif M, Saeed M H B, et al. Clinical profile and outcome of neonatal pneumothorax in resource-limited neonatal intensive care unit[J]. J Matern Fetal Neonatal Med, 2022, 35(17): 3373-3378.
[9]Munyuzangabo M, Gaffey M F, Khalifa D S, et al. Delivering maternal and neonatal health interventions in conflict settings: a systematic review[J]. BMJ Glob Health, 2021, 5(1): e003750.
[10]Wang J, Chen H, Li M, et al. Investigation of the Rapid Emergence of Colistin Resistance in a Newborn Infected with KPC-2-Producing Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae[J]. J Glob Antimicrob Resist, 2024, 38(1）: 265-270. doi:10.1016/j.jgar.
2024. 05. 021
[11]Urs R C, Evans D J, Bradshaw T K, et al. Inhaled corticosteroids to improve lung function in children (aged 6-12 years) who were
born very preterm (PICSI): a randomised, double-blind, placebo-controlled trial[J]. Lancet Child Adolesc Health, 2023, 7(8): 567-576.
[12]Yang X, Gao L. Effect of azithromycin combined with fluticasone propionate aerosol inhalation on immune function in children
with chronic cough caused by Mycoplasma pneumoniae infection[J]. Eur J Pediatr, 2025, 184(2): 155.
[13]Xu XJ, Liu W, Liland S. MicroRNA-29a-3p Accelerates Inflammatory Damage in Neonatal Pneumonia Via Targeting Krüppel-like
Factor 4[J]. Iran J Allergy Asthma Immunol, 2023,22(5):440-451.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
